Table 1.

Study population characteristics

	All patients withhematologicmalignancy	Lymphoma patients	Myeloma patients
	(n = 137)	(n = 102)	(n = 34)
Age (years)	68.5 (58.4–76.1)	68.4 (58.4–76.8)	68.3 (56.1–74.9)
Male	75 (54.7%)	52 (51.0%)	22 (64.7%)
PET-1 patients  Days from Vac-1 to PET-CT	51 (37.2%) 10 (6–15)	39 (38.2%) 10 (5–15)	11 (32.4%) 12 (8–16)
PET-2 patients  Days from Vac-2 to PET-CT	86 (62.8%) 19 (10–27)	63 (61.8%) 17 (10–27)	23 (67.6%) 22 (11–30)
Staging Monitor response to therapy Recurrence Follow-up with NED	26 (19.0%) 59 (43.1%) 22 (16.1%) 30 (21.9%)	20 (19.6%) 38 (37.3%) 18 (17.6%) 26 (25.5%)	6 (17.6%) 20 (58.8%) 4 (11.8%) 4 (11.8%)

Categorical variables are reported as frequency and percentage; Continuous variables are reported as median and IQR. Vac-1, first vaccine dose; Vac-2, booster vaccine dose; NED, no evidence of disease